The Therapeutic Goods Administration (TGA) received complaints about the ‘unlawful’ advertising of medical cannabis-based products, and TGA is now checking on this situation.
The TGA said,
“It has written to a number of entities in relation to non-compliance with the law with instruction to cease unlawful behavior.”
And on Tuesday, the regulator also said in a statement:
“The majority of respondents have brought themselves into compliance. For those that have not, we are considering appropriate action.”
According to the TGA, criminal offences and civil penalties are applied to breaches of the Narcotic Drugs Act and the Therapeutic Goods Act.
The consumer is the priority in the review of complaints, as the TGA said:
“May be at risk because the medicinal cannabis products offered for sale have not been through regulatory checks.”
In Australia, the advertisement about regulated medicines, including medical cannabis products, are under strict control rule. As Rhys Cohen, principal consultant for FreshLeaf Analytics, demonstrated:
“The TGA clarified how these regulations apply to the medical cannabis industry back in November 2019. In short, it is a breach of the regulations to advertise or promote the use of a specific prescription medicine or a class of prescription medicines to the general public.”
Due to the investigation of unlawful cannabis advertisements, the TGA expands the number of quality inspections for medical cannabis importation.
Although the local factories continue to develop cannabis production, a majority of medical cannabis in Australia is imported.
Last year, about 3,700 liters (977 gallons) of medical cannabis oil products and 204 kilograms of cannabis flowers were imported from Canada for both medical and scientific use in Australia.
This article is issued by Marijuana Business Journey, for more information, please check: